ASCO 2022: Highlights and analysis

Elacestrant significantly prolongs PFS for ER+/HER2- metastatic breast cancer without prior chemotherapy patients

ASCO 2022: Breast cancer highlights

Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

Comment: Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients

Sacituzumab goviteca provides clinically meaningful PFS benefit for hormone receptor HR+/HER2‐ advanced breast cancer patients

Comment: Sacituzumab govitecan for HR+/HER2‐ advanced breast cancer

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Cancer Services Delivery: Focus on India